Proposed Targets. Immunocore understands that Lilly has nominated the Initial Targets and Immunocore acknowledges receipt of the Nomination Notices set out in Exhibit H in relation to the two (2) Initial Targets as of the Effective Date.
Proposed Targets. Prior to nomination of a Target (whether pursuant to Section 3.2.6 or Section 3.2.8), AbbVie may, in its discretion, disclose a Target it is considering for potential nomination (a “Proposed Target”) to the Gatekeeper and request in writing that the Gatekeeper confirm if the Proposed Target is on the list of Unavailable Targets. Within [***] Business Days following the Gatekeeper’s receipt of the identity of a Proposed Target from AbbVie, the Gatekeeper shall verify whether such Proposed Target is on the list of Unavailable Targets and notify AbbVie in writing whether such Proposed Target is or is not on the list of Unavailable Targets. Notwithstanding anything herein to the contrary (a) AbbVie shall have no obligation to nominate any Proposed Targets, and (b) in no way shall a request by AbbVie with respect to a Proposed Target under this Section 3.2.5 be deemed to be a nomination of the Target as an Accepted Target (and such Target shall not be considered nominated unless and until it is formally nominated in accordance with the terms and conditions set forth in Section 3.2.6).
Proposed Targets. 2.4.1 In the event that Sanofi wishes to (a) select a Target as an Additional Collaboration Target in accordance with Section 2.2.2 (Additional Collaboration Targets), (b) exercise its Collaboration Target Substitution Right under Section 2.2.3 (Collaboration Target Substitution Right) for a Collaboration Target, (c) select a Target as a Reserved Target under Section 2.3.2 (Additional Reserved Targets; Subsequent Years), or (d) exercise its Reserved Target Substitution Right under Section 2.3.3 (Reserved Target Substitution Right) for a Reserved Target, then in each case Sanofi shall have the right to first undertake the Gatekeeper process described in 2.5 (Gatekeeper), provided that for any desired exercise by Sanofi of the rights described in (a)-(d) above, Sanofi shall provide email notice to [*] (each such notice a “Proposed Available Target Notice”) of the identity of such Target (each a “Proposed Target”) and which of the Sanofi rights described in (a)-(d) above Sanofi is exercising. If such Proposed Target is already a Reserved Target at the time of delivery of such Proposed Available Target Notice to [*], then Sanofi will be deemed to have exercised its applicable right described in (a) or (b) with respect to such Target upon delivery of such written notice. If such Proposed Target is not a Reserved Target and is an Excluded Target at the time of delivery of such Proposed Available Target Notice to [*], then Sanofi shall not have the right to exercise its applicable right described in (a)-(d) with respect to such Proposed Target. If such Target is an Available Target at the time of delivery of such Proposed Available Target Notice to [*], then Sanofi will be deemed to have exercised its applicable right described in (a)-(d) with respect to such Available Target upon delivery of such Proposed Available Target Notice. [*]
Proposed Targets. With respect to any Proposed Target, within [**] after any Proposed Target Notice provided by Xxxxxxx to Mersana under Section 3.2.1 or 3.2.2 or after receipt of a Post-HSR Synaffix Notice under Section 3.6.3, Mersana will inquire with Synaffix (under the procedure set forth in Section 2.2(b) of the Synaffix Agreement) whether such Proposed Target is a Synaffix Unavailable Target. If such Proposed Target is a Synaffix Unavailable Target, Xxxxxxx shall have the right to either (i) in its sole discretion, decline to select such Proposed Target as a Target, or (ii) designate the Proposed Target as a Non-Synaffix Target and, if permitted under Section 3.4.3(b) and in accordance with Section 3.4.3(b), select such Proposed Target as a Target, but subject to, for clarity, the restrictions on use of Licensed Technology (as defined in the Synaffix Agreement) set forth in Section 3.4.3(a). If such Proposed Target is a Synaffix Available Target, then such Proposed Target shall automatically become an Initial Target as set forth in Section 3.2.4.
Proposed Targets to LG Chem for the first year of the Research Term using its best efforts to provide such Proposed Targets within sixty (60) days after the Effective Date and in no event later than ninety (90) days after the Effective Date. In each subsequent year of the Research Term, Elitra shall provide the initial [...***...] Proposed Targets to LG Chem within thirty (30) days of the anniversary of the Effective Date that marks the commencement of such year. LG Chem shall have the right to reject, in good faith, up to [...***...]
Proposed Targets for the remaining of FY18 (Q2-Q3-Q4) Provided enough LLINs are made available by the MoH, HFA proposes that distribution in the remaining 8 (eight) provinces be divided as follows: o Emergency response: February-March: Huambo o Phase 3: April-May-June 2018: Cuando Cubango, Cabinda, Bie, and Bengo o Phase 4: July-August-September 2018: Lunda Norte, Lunda Sul and Moxico Targets for remainder of FY18 (Q2-Q3-Q4): o Distribution of 4,573,897 ITNs (provided enough LLINs are made available by the MoH) o Population to be covered: 6,772,276 beneficiaries (204,179 pregnant women + 1,595,558 children >5) o 6,803 community HW (activists and field supervisors) to be trained in communication, registration and distribution o Distribution Tool Kit: to be completed and tested during the first 2 quarters of FY18 and delivered to NMCP in Q3 to assist in future mass distribution campaigns. o Social Behavior Change Communication campaign: pre- and post-campaign plan to be updated and implemented in coordination with NMCP and other communication partners (ADECOS, UNITEL).
